Clinical Trial Update: A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy [Phase 2]

View source ↗

Summary

This Phase 2 multi-center trial evaluated the efficacy and safety of a CCR2/5 receptor antagonist in adults with type 2 diabetes and overt nephropathy. The stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Nephropathy

Drugs mentioned

• CCR2/5 receptor antagonist (investigational)

Snippet

Sponsor: Pfizer | Conditions: Diabetic Nephropathy | Phase 2 | Status: COMPLETED | Results posted: 2015-10-21